2 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow Replicor Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients REP 2139-Ca, Zadaxin, Pegasys - Hepatitis B, Chronic | Phase 1 / Phase 2 | Completed | Replicor Inc. | 12 | 2011-08-01 | 2016-01-05 |
| Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients REP 2055 - Hepatitis B, Chronic | Phase 1 / Phase 2 | Completed | Replicor Inc. | 8 | 2009-01-01 | 2016-01-05 |
REP 2055 (1) · Thymalfasin (1) · peginterferon alfa-2a (1)
Bangladesh (2)